Gallium Maltolate for Glioblastoma

This trial explores how effectively gallium maltolate, a potential new treatment, reaches brain tumors in individuals with recurring glioblastoma, an aggressive brain cancer. Participants will take the treatment for 14 days before surgery to assess its penetration into the tumor. The trial seeks individuals who have already received standard treatments for glioblastoma, such as radiation and temozolomide chemotherapy, and have stable symptoms without recent worsening. As an Early Phase 1 trial, this research aims to understand how the treatment works in people, offering participants a chance to be among the first to receive this new therapy.

You will need to stop taking oral iron supplements or iron chelators at least one week before starting the trial medication. The protocol does not specify other medication restrictions, but you should discuss your current medications with the study team.

Research has shown that gallium maltolate (GaM) is generally safe for treating glioblastoma, a type of brain cancer. Studies have found that patients tolerate GaM well. Early results confirm its safety, with no major side effects reported.

In one study, patients who received GaM lived about 14 months, indicating effectiveness without causing serious harm. This outcome is a positive indicator of its safety.

Gallium Maltolate is unique because it uses gallium, a metal that disrupts cancer cell metabolism by mimicking iron, which is essential for tumor growth. Unlike standard treatments for glioblastoma, such as temozolomide and radiation therapy, Gallium Maltolate offers a novel mechanism of action by specifically targeting the tumor's iron uptake processes. Researchers are excited about this approach because it could lead to more effective ways to halt tumor growth without affecting healthy cells as much as traditional therapies do.

Research has shown that gallium maltolate may help treat glioblastoma, a type of brain cancer. Studies have found that gallium maltolate can slow tumor growth and extend survival in animal tests. In one study, patients with recurring glioblastoma lived about 14 months on average after starting treatment with gallium maltolate. The treatment is usually well-tolerated and easily absorbed when taken orally. Early results suggest that gallium maltolate might benefit those with difficult-to-treat forms of this cancer. Participants in this trial will receive gallium maltolate for 14 days before surgical intervention.¹³⁴⁶⁷